Drug
Later-line therapy
Later-line therapy is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph not_applicable
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)
Highest Phase Reached
UnknownTrial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Recruiting2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
N/A
Trials by Phase
N/A3 (100.0%)
Trials by Status
recruiting267%
unknown133%
Recent Activity
2 active trials
Showing 3 of 3
unknownnot_applicable
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
NCT05802420
recruitingnot_applicable
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
NCT05802407
recruitingnot_applicable
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT05802394
Clinical Trials (3)
Showing 3 of 3 trials
NCT05802420Not Applicable
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
NCT05802407Not Applicable
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
NCT05802394Not Applicable
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3